Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk COVID-19 patients in north west London: a retrospective cohort study
Dr Myriam Drysdale, Evgeniy R Galimov, Marcus James Yarwood, Vishal Patel, Bethany Levick, Daniel C Gibbons, Jonathan D Watkins, Sophie Young, Benjamin F Pierce, Emily J Lloyd, William Kerr, Helen J Birch, Tahereh Kamalati, Stephen J Brett
BMJ Open Respiratory Research, doi:10.1136/bmjresp-2023-002238
Background We assessed the effectiveness of sotrovimab vs no early COVID-19 treatment in highest-risk COVID-19 patients during Omicron predominance. Methods Retrospective cohort study using the Discover dataset in North West London. Included patients were nonhospitalised, aged ≥12 years and met ≥1 National Health Service highest-risk criterion for sotrovimab treatment. We used Cox proportional hazards models to compare HRs of 28-day COVID-19-related hospitalisation/death between highest-risk sotrovimab-treated and untreated patients. Age, renal disease and Omicron subvariant subgroup analyses were performed. Results We included 599 sotrovimab-treated patients and 5191 untreated patients. Compared with untreated patients, the risk of COVID-19 hospitalisation/death (HR 0.50, 95% CI 0.24, 1.06; p=0.07) and the risk of COVID-19 hospitalisation (HR 0.43, 95% CI 0.18, 1.00; p=0.051) were both lower in the sotrovimab-treated group; however, statistical significance was not reached. In the ≥65 years and renal disease subgroups, sotrovimab was associated with a significantly reduced risk of COVID-19 hospitalisation, by 89% (HR 0.11, 95% CI 0.02, 0.82; p=0.03) and 82% (HR 0.18, 95% CI 0.05, 0.62; p=0.007), respectively. Conclusions Risk of COVID-19 hospitalisation in sotrovimab-treated patients aged ≥65 years and with renal disease was significantly lower compared with untreated patients. Overall, risk of hospitalisation was also lower for sotrovimab-treated patients, but statistical significance was not reached. ⇒ This study begins to fill the evidence gap in relation to early treatments for mild-to-moderate COVID-19, particularly their effectiveness against disease caused by Omicron variants to date. on April 14,
Contributors MD, MJY, VP, BL, DCG, JDW, SY, BFP, HJB, TK and SJB designed the study; ERG performed inverse probability of treatment weighted survival analysis; MJY performed descriptive analysis; MD, ERG, MJY, BL, DCG, JDW, SY, BFP, EJL, WK, TK and SJB interpreted results. MD is responsible for the overall content as the guarantor. All authors took part in drafting, revising or critically reviewing the manuscript; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Competing interests MD, DCG, EJL, WK and HJB are employees of, and/or shareholders in, GSK. VP was an employee of GSK at the time of the study and is now an employee of KVM Analytics. ERG, MJY, JDW, SY, BFP and TK are (or were at time of study) employees of Imperial College Health Partners, which received funding from GSK and Vir Biotechnology to conduct the study. BL is an employee of OPEN Health, which received funding from GSK and Vir Biotechnology, Inc, to conduct the study. A consultancy fee was paid to SJB's institutional account. Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Patient consent for publication Not applicable. Provenance and peer review Not commissioned; externally peer reviewed. Data availability statement Data are available upon reasonable request. The..
References
Austin, Stuart, Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies, Stat Med,
doi:10.1002/sim.6607Bottle, Cohen, Lucas, How an electronic health record became a real-world research resource: comparison between London's whole systems integrated care database and the clinical practice research Datalink, BMC Med Inform Decis Mak,
doi:10.1186/s12911-020-1082-7Bruel, Hadjadj, Maes, Serum neutralization of SARS-Cov-2 Omicron Sublineages BA.1 and BA.2 in patients receiving Monoclonal antibodies, Nat Med,
doi:10.1038/s41591-022-01792-5Case, Mackin, Errico, Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-Cov-2 Omicron lineage strains, Nat Commun,
doi:10.1038/s41467-022-31615-7Cathcart, Havenar-Daughton, Lempp, The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-Cov-2
Cheng, Reyes, Satram, Real-world effectiveness of sotrovimab for the early treatment of COVID-19 during SARS-Cov-2 Delta and Omicron waves in the USA, Infect Dis Ther,
doi:10.1007/s40121-022-00755-0Drysdale, Gibbons, Singh, Real-world effectiveness of Sotrovimab for the treatment of SARS-Cov-2 infection during Omicron BA.2 Subvariant predominance: a systematic literature review, Infection,
doi:10.1007/s15010-023-02098-5Drysdale, for SARS-Cov-2 infection during the Omicron wave in England (Qcovid4): cohort study, BMJ Open Respir Res,
doi:10.1136/bmj-2022-072976Gaudinski, Coates, Houser, Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults, PLoS Med,
doi:10.1371/journal.pmed.1002493Gupta, Gonzalez-Rojas, Juarez, Effect of Sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial, JAMA,
doi:10.1001/jama.2022.2832Harman, Nash, Webster, Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with sotrovimab in the community in England, Influenza Other Respir Viruses,
doi:10.1111/irv.13150Hippisley-Cox, Khunti, Sheikh, Risk prediction of COVID-19 related death or hospital admission in adults testing on April 14, 2024 by guest
Ko, Pegu, Rudicell, Enhanced neonatal Fc receptor function improves protection against primate SHIV infection, Nature,
doi:10.1038/nature13612Mendiola-Pastrana, López-Ortiz, De La Loza-Zamora, SARS-Cov-2 variants and clinical outcomes: a systematic review, Life,
doi:10.3390/life12020170Paraskevis, Gkova, Mellou, Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID-19 in patients at high risk, J Infect Dis,
doi:10.1093/infdis/jiad324Patel, Levick, Boult, Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in Nhs hospitals in England
Patel, Yarwood, Levick, Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving Sotrovimab, oral Antivirals or no treatment in England
Tazare, Nab, Zheng, Effectiveness of Sotrovimab and Molnupiravir in community settings in England across the Omicron Ba.1 and Ba.2 Sublineages: emulated target trials using the OpenSAFELY platform
Wai, Chan, Cheung, Association of molnupiravir and nirmatrelvir-ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19, Lancet Reg Health West Pac,
doi:10.1016/j.lanwpc.2022.100602Xu, Ross, Raebel, Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals, Value Health,
doi:10.1111/j.1524-4733.2009.00671.xYip, Lui, Lai, Impact of the use of oral antiviral agents on the risk of hospitalization in community Coronavirus disease, Clinical Infectious Diseases,
doi:10.1093/cid/ciac687Young-Xu, Korves, Zwain, Effectiveness of sotrovimab in preventing COVID-19-related hospitalizations or deaths among U.S. veterans, Open Forum Infect Dis,
doi:10.1093/ofid/ofad605Zheng, Campbell, Carr, Comparative effectiveness of Sotrovimab and Molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised patients on kidney replacement therapy: observational cohort study using the Opensafely-UKRR linked platform and SRR database, Clinical Kidney Journal,
doi:10.1093/ckj/sfad184Zheng, Green, Tazare, Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in patients in the community: observational cohort study with the opensafely platform, BMJ,
doi:10.1136/bmj-2022-071932Zheng, Tazare, Nab, Comparative effectiveness of Nirmatrelvir/Ritonavir versus Sotrovimab and Molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the Opensafely platform, Lancet Reg Health Eur,
doi:10.1016/j.lanepe.2023.100741{ 'indexed': {'date-parts': [[2024, 4, 5]], 'date-time': '2024-04-05T00:44:30Z', 'timestamp': 1712277870202},
'reference-count': 39,
'publisher': 'BMJ',
'issue': '1',
'license': [ { 'start': { 'date-parts': [[2024, 4, 4]],
'date-time': '2024-04-04T00:00:00Z',
'timestamp': 1712188800000},
'content-version': 'unspecified',
'delay-in-days': 3,
'URL': 'http://creativecommons.org/licenses/by-nc/4.0/'}],
'funder': [ {'DOI': '10.13039/100019650', 'name': 'Vir Biotechnology', 'doi-asserted-by': 'publisher'},
{'name': 'GSK', 'award': ['219543']}],
'content-domain': {'domain': ['bmj.com'], 'crossmark-restriction': True},
'accepted': {'date-parts': [[2024, 3, 14]]},
'published-print': {'date-parts': [[2024, 4]]},
'abstract': '<jats:sec><jats:title>Background</jats:title><jats:p>We assessed the effectiveness of '
'sotrovimab vs no early COVID-19 treatment in highest-risk COVID-19 patients during Omicron '
'predominance.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Retrospective '
'cohort study using the Discover dataset in North West London. Included patients were '
'non-hospitalised, aged ≥12 years and met ≥1 National Health Service highest-risk criterion '
'for sotrovimab treatment. We used Cox proportional hazards models to compare HRs of 28-day '
'COVID-19-related hospitalisation/death between highest-risk sotrovimab-treated and untreated '
'patients. Age, renal disease and Omicron subvariant subgroup analyses were '
'performed.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We included '
'599 sotrovimab-treated patients and 5191 untreated patients. Compared with untreated '
'patients, the risk of COVID-19 hospitalisation/death (HR 0.50, 95% CI 0.24, 1.06; p=0.07) and '
'the risk of COVID-19 hospitalisation (HR 0.43, 95%\u2009CI 0.18, 1.00; p=0.051) were both '
'lower in the sotrovimab-treated group; however, statistical significance was not reached. In '
'the ≥65 years and renal disease subgroups, sotrovimab was associated with a significantly '
'reduced risk of COVID-19 hospitalisation, by 89% (HR 0.11, 95%\u2009CI 0.02, 0.82; p=0.03) '
'and 82% (HR 0.18, 95%\u2009CI 0.05, 0.62; p=0.007), '
'respectively.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Risk '
'of COVID-19 hospitalisation in sotrovimab-treated patients aged ≥65 years and with renal '
'disease was significantly lower compared with untreated patients. Overall, risk of '
'hospitalisation was also lower for sotrovimab-treated patients, but statistical significance '
'was not reached.</jats:p></jats:sec>',
'DOI': '10.1136/bmjresp-2023-002238',
'type': 'journal-article',
'created': {'date-parts': [[2024, 4, 4]], 'date-time': '2024-04-04T17:35:17Z', 'timestamp': 1712252117000},
'page': 'e002238',
'update-policy': 'http://dx.doi.org/10.1136/crossmarkpolicy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk '
'COVID-19 patients in north west London: a retrospective cohort study',
'prefix': '10.1136',
'volume': '11',
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-8994-2816',
'authenticated-orcid': False,
'given': 'Myriam',
'family': 'Drysdale',
'sequence': 'first',
'affiliation': []},
{'given': 'Evgeniy R', 'family': 'Galimov', 'sequence': 'additional', 'affiliation': []},
{'given': 'Marcus James', 'family': 'Yarwood', 'sequence': 'additional', 'affiliation': []},
{'given': 'Vishal', 'family': 'Patel', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-6371-8744',
'authenticated-orcid': False,
'given': 'Bethany',
'family': 'Levick',
'sequence': 'additional',
'affiliation': []},
{'given': 'Daniel C', 'family': 'Gibbons', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jonathan D', 'family': 'Watkins', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sophie', 'family': 'Young', 'sequence': 'additional', 'affiliation': []},
{'given': 'Benjamin F', 'family': 'Pierce', 'sequence': 'additional', 'affiliation': []},
{'given': 'Emily J', 'family': 'Lloyd', 'sequence': 'additional', 'affiliation': []},
{'given': 'William', 'family': 'Kerr', 'sequence': 'additional', 'affiliation': []},
{'given': 'Helen J', 'family': 'Birch', 'sequence': 'additional', 'affiliation': []},
{'given': 'Tahereh', 'family': 'Kamalati', 'sequence': 'additional', 'affiliation': []},
{'given': 'Stephen J', 'family': 'Brett', 'sequence': 'additional', 'affiliation': []}],
'member': '239',
'published-online': {'date-parts': [[2024, 4, 4]]},
'reference': [ { 'key': '2024040410350981000_11.1.e002238.1',
'unstructured': 'World Health Organization . Coronavirus disease (COVID-19) pandemic. '
'Available: https://www.who.int/europe/emergencies/situations/covid-19 '
'[Accessed 5 Jul 2023].'},
{ 'key': '2024040410350981000_11.1.e002238.2',
'unstructured': 'Department of Health and Social Care . Higher-risk patients eligible for '
'COVID-19 treatments: independent advisory group report. Available: '
'https://www.gov.uk/government/publications/higher-risk-patients-eligible-for-covid-19-treatments-independent-advisory-group-report '
'[Accessed 5 Jul 2023].'},
{ 'key': '2024040410350981000_11.1.e002238.3',
'unstructured': 'Department of Health and . Interim clinical commissioning policy: '
'Antivirals or Neutralising Monoclonal antibodies for non-hospitalised '
'patients with COVID-19. Available: '
'https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAttachment.aspx?Attachment_id=104044 '
'[Accessed 5 Jul 2023].'},
{ 'key': '2024040410350981000_11.1.e002238.4',
'unstructured': 'Medicines and Healthcare products Regulatory Agency . Summary of product '
'characteristics for Xevudy. Available: '
'https://www.gov.uk/government/publications/regulatory-approval-of-xevudy-sotrovimab/summary-of-product-characteristics-for-xevudy '
'[Accessed 5 Jul 2023].'},
{ 'key': '2024040410350981000_11.1.e002238.5',
'unstructured': 'Medicines and Healthcare products Regulatory Agency . First oral '
'antiviral for COVID-19, Lagevrio (Molnupiravir), approved by MHRA. '
'available at. n.d. Available: '
'https://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra#:~:text=and%20licensing%20guidance-,First%20oral%20antiviral%20for%20COVID%2D19%2C%20Lagevrio%20(molnupiravir),review%20of%20the%20available%20evidence'},
{ 'key': '2024040410350981000_11.1.e002238.6',
'unstructured': 'Medicines and Healthcare products Regulatory Agency . Oral COVID-19 '
'antiviral, Paxlovid, approved by UK regulator. Available: '
'https://www.gov.uk/government/news/oral-covid-19-antiviral-paxlovid-approved-by-uk-regulator '
'[Accessed 5 Jul 2023].'},
{ 'key': '2024040410350981000_11.1.e002238.7',
'doi-asserted-by': 'crossref',
'DOI': '10.1371/journal.pmed.1002493',
'article-title': 'Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal '
'antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults',
'volume': '15',
'author': 'Gaudinski',
'year': '2018',
'journal-title': 'PLoS Med'},
{ 'key': '2024040410350981000_11.1.e002238.8',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/nature13612'},
{ 'key': '2024040410350981000_11.1.e002238.9',
'doi-asserted-by': 'crossref',
'first-page': '290',
'DOI': '10.1038/s41586-020-2349-y',
'article-title': 'Cross-neutralization of SARS-Cov-2 by a human Monoclonal SARS-Cov '
'antibody',
'volume': '583',
'author': 'Pinto',
'year': '2020',
'journal-title': 'Nature'},
{ 'key': '2024040410350981000_11.1.e002238.10',
'doi-asserted-by': 'crossref',
'unstructured': 'Cathcart AL , Havenar-Daughton C , Lempp FA , et al . The dual function '
'monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro '
'and in vivo activity against SARS-Cov-2. bioRxiv [Preprint]. '
'doi:10.1101/2021.03.09.434607',
'DOI': '10.1101/2021.03.09.434607'},
{ 'key': '2024040410350981000_11.1.e002238.11',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jama.2022.2832'},
{ 'key': '2024040410350981000_11.1.e002238.12',
'unstructured': 'National Institute for Health and Care Excellence . Final draft '
'guidance: Therapeutics for people with COVID-19. Available: '
'https://www.nice.org.uk/guidance/ta878/documents/final-appraisal-determination-document '
'[Accessed 5 Jul 2023].'},
{ 'key': '2024040410350981000_11.1.e002238.13',
'article-title': 'SARS-Cov-2 variants and clinical outcomes: a systematic review',
'volume': '12',
'author': 'Mendiola-Pastrana',
'year': '2022',
'journal-title': 'Life (Basel)'},
{ 'key': '2024040410350981000_11.1.e002238.14',
'unstructured': 'World Health Organization . Weekly epidemiological update on COVID-19. '
'2022. Available: '
'https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---25-january-2022 '
'[Accessed 5 Jul 2023].'},
{ 'key': '2024040410350981000_11.1.e002238.15',
'unstructured': 'World Health Organization . Weekly epidemiological update on COVID-19. '
'2022. Available: '
'https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---22-march-2022 '
'[Accessed 5 2023].'},
{ 'key': '2024040410350981000_11.1.e002238.16',
'doi-asserted-by': 'publisher',
'DOI': '10.1126/science.adc9127'},
{ 'key': '2024040410350981000_11.1.e002238.17',
'unstructured': 'UK Health Security Agency . SARS-Cov-2 variants of concern and variants '
'under investigation in England: technical briefing 49. Available: '
'https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1129169/variant-technical-briefing-49-11-january-2023.pdf '
'[Accessed 5 2023].'},
{ 'key': '2024040410350981000_11.1.e002238.18',
'doi-asserted-by': 'crossref',
'first-page': '1',
'DOI': '10.1007/s15010-023-02098-5',
'article-title': 'Real-world effectiveness of Sotrovimab for the treatment of SARS-Cov-2 '
'infection during Omicron BA.2 Subvariant predominance: a systematic '
'literature review',
'volume': '52',
'author': 'Drysdale',
'year': '2024',
'journal-title': 'Infection'},
{ 'key': '2024040410350981000_11.1.e002238.19',
'doi-asserted-by': 'crossref',
'unstructured': 'Patel V , Yarwood MJ , Levick B , et al . Characteristics and outcomes '
'of patients with COVID-19 at high-risk of disease progression receiving '
'Sotrovimab, oral Antivirals or no treatment in England. medRxiv '
'[Preprint]. doi:10.1101/2022.11.28.22282808',
'DOI': '10.1101/2022.11.28.22282808'},
{ 'key': '2024040410350981000_11.1.e002238.20',
'doi-asserted-by': 'crossref',
'DOI': '10.1186/s12911-020-1082-7',
'article-title': 'How an electronic health record became a real-world research resource: '
'comparison between London’s whole systems integrated care database and '
'the clinical practice research Datalink',
'volume': '20',
'author': 'Bottle',
'year': '2020',
'journal-title': 'BMC Med Inform Decis Mak'},
{ 'key': '2024040410350981000_11.1.e002238.21',
'unstructured': 'Discover-NOW . Our Dataset: linked data. Available: '
'https://discover-now.co.uk/the-data [Accessed 5 2023].'},
{ 'key': '2024040410350981000_11.1.e002238.22',
'unstructured': 'UK Health Security Agency . SARS-Cov-2 variants of concern and variants '
'under investigation in England: technical briefing 45. Available: '
'https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1115071/Technical-Briefing-45-9September2022.pdf '
'[Accessed 5 2023].'},
{ 'key': '2024040410350981000_11.1.e002238.23',
'doi-asserted-by': 'publisher',
'DOI': '10.1111/j.1524-4733.2009.00671.x'},
{ 'key': '2024040410350981000_11.1.e002238.24',
'doi-asserted-by': 'publisher',
'DOI': '10.1002/sim.6607'},
{ 'key': '2024040410350981000_11.1.e002238.25',
'doi-asserted-by': 'crossref',
'DOI': '10.1136/bmj-2022-072976',
'article-title': 'Risk prediction of COVID-19 related death or hospital admission in '
'adults testing positive for SARS-Cov-2 infection during the Omicron '
'wave in England (Qcovid4): cohort study',
'volume': '381',
'author': 'Hippisley-Cox',
'year': '2023',
'journal-title': 'BMJ'},
{ 'key': '2024040410350981000_11.1.e002238.26',
'doi-asserted-by': 'crossref',
'first-page': '2048',
'DOI': '10.1093/ckj/sfad184',
'article-title': 'Comparative effectiveness of Sotrovimab and Molnupiravir for preventing '
'severe COVID-19 outcomes in non-hospitalised patients on kidney '
'replacement therapy: observational cohort study using the '
'Opensafely-UKRR linked platform and SRR database',
'volume': '16',
'author': 'Zheng',
'year': '2023',
'journal-title': 'Clinical Kidney Journal'},
{ 'key': '2024040410350981000_11.1.e002238.27',
'doi-asserted-by': 'crossref',
'first-page': '607',
'DOI': '10.1007/s40121-022-00755-0',
'article-title': 'Real-world effectiveness of sotrovimab for the early treatment of '
'COVID-19 during SARS-Cov-2 Delta and Omicron waves in the USA',
'volume': '12',
'author': 'Cheng',
'year': '2023',
'journal-title': 'Infect Dis Ther'},
{ 'key': '2024040410350981000_11.1.e002238.28',
'doi-asserted-by': 'crossref',
'DOI': '10.1093/ofid/ofad605',
'article-title': 'Effectiveness of sotrovimab in preventing COVID-19-related '
'hospitalizations or deaths among U.S. veterans',
'volume': '10',
'author': 'Young-Xu',
'year': '2023',
'journal-title': 'Open Forum Infect Dis'},
{ 'key': '2024040410350981000_11.1.e002238.29',
'doi-asserted-by': 'crossref',
'DOI': '10.1111/irv.13150',
'article-title': 'Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 '
'cases treated with sotrovimab in the community in England',
'volume': '17',
'author': 'Harman',
'year': '2023',
'journal-title': 'Influenza Other Respir Viruses'},
{ 'key': '2024040410350981000_11.1.e002238.30',
'doi-asserted-by': 'crossref',
'unstructured': 'Patel V , Levick B , Boult S , et al . Characteristics and outcomes of '
'COVID-19 patients presumed to be treated with sotrovimab in Nhs '
'hospitals in England. medRxiv [Preprint]. '
'doi:10.1101/2023.02.08.23285654',
'DOI': '10.1101/2023.02.08.23285654'},
{ 'key': '2024040410350981000_11.1.e002238.31',
'doi-asserted-by': 'crossref',
'DOI': '10.1136/bmj-2022-071932',
'article-title': 'Comparative effectiveness of sotrovimab and molnupiravir for prevention '
'of severe COVID-19 outcomes in patients in the community: observational '
'cohort study with the opensafely platform',
'volume': '379',
'author': 'Zheng',
'year': '2022',
'journal-title': 'BMJ'},
{ 'key': '2024040410350981000_11.1.e002238.32',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.lanepe.2023.100741',
'article-title': 'Comparative effectiveness of Nirmatrelvir/Ritonavir versus Sotrovimab '
'and Molnupiravir for preventing severe COVID-19 outcomes in '
'non-hospitalised high-risk patients during Omicron waves: observational '
'cohort study using the Opensafely platform',
'volume': '34',
'author': 'Zheng',
'year': '2023',
'journal-title': 'Lancet Reg Health Eur'},
{ 'key': '2024040410350981000_11.1.e002238.33',
'doi-asserted-by': 'crossref',
'unstructured': 'Tazare J , Nab L , Zheng B , et al . Effectiveness of Sotrovimab and '
'Molnupiravir in community settings in England across the Omicron Ba.1 '
'and Ba.2 Sublineages: emulated target trials using the OpenSAFELY '
'platform. Epidemiology [Preprint]. doi:10.1101/2023.05.12.23289914',
'DOI': '10.1101/2023.05.12.23289914'},
{ 'key': '2024040410350981000_11.1.e002238.34',
'doi-asserted-by': 'crossref',
'first-page': '1297',
'DOI': '10.1038/s41591-022-01792-5',
'article-title': 'Serum neutralization of SARS-Cov-2 Omicron Sublineages BA.1 and BA.2 in '
'patients receiving Monoclonal antibodies',
'volume': '28',
'author': 'Bruel',
'year': '2022',
'journal-title': 'Nat Med'},
{ 'key': '2024040410350981000_11.1.e002238.35',
'doi-asserted-by': 'crossref',
'DOI': '10.1038/s41467-022-31615-7',
'article-title': 'Resilience of S309 and AZD7442 monoclonal antibody treatments against '
'infection by SARS-Cov-2 Omicron lineage strains',
'volume': '13',
'author': 'Case',
'year': '2022',
'journal-title': 'Nat Commun'},
{ 'key': '2024040410350981000_11.1.e002238.36',
'doi-asserted-by': 'crossref',
'first-page': '1667',
'DOI': '10.1093/infdis/jiad324',
'article-title': 'Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as '
'treatments for COVID-19 in patients at high risk',
'volume': '228',
'author': 'Paraskevis',
'year': '2023',
'journal-title': 'J Infect Dis'},
{ 'key': '2024040410350981000_11.1.e002238.37',
'doi-asserted-by': 'crossref',
'first-page': 'e26',
'DOI': '10.1093/cid/ciac687',
'article-title': 'Impact of the use of oral antiviral agents on the risk of '
'hospitalization in community Coronavirus disease',
'volume': '76',
'author': 'Yip',
'year': '2023',
'journal-title': 'Clinical Infectious Diseases'},
{ 'key': '2024040410350981000_11.1.e002238.38',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.lanwpc.2022.100602',
'article-title': 'Association of molnupiravir and nirmatrelvir-ritonavir with preventable '
'mortality, hospital admissions and related avoidable healthcare system '
'cost among high-risk patients with mild to moderate COVID-19',
'volume': '30',
'author': 'Wai',
'year': '2023',
'journal-title': 'Lancet Reg Health West Pac'},
{ 'key': '2024040410350981000_11.1.e002238.39',
'unstructured': 'Office for National Statistics . Coronavirus (COVID-19) latest insights: '
'hospitals. Available: '
'https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/hospitals '
'[Accessed 5 2023].'}],
'container-title': 'BMJ Open Respiratory Research',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1136/bmjresp-2023-002238',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 4, 4]],
'date-time': '2024-04-04T17:36:05Z',
'timestamp': 1712252165000},
'score': 1,
'resource': {'primary': {'URL': 'https://bmjopenrespres.bmj.com/lookup/doi/10.1136/bmjresp-2023-002238'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 4]]},
'references-count': 39,
'journal-issue': { 'issue': '1',
'published-online': {'date-parts': [[2024, 4, 4]]},
'published-print': {'date-parts': [[2024, 4]]}},
'alternative-id': ['10.1136/bmjresp-2023-002238'],
'URL': 'http://dx.doi.org/10.1136/bmjresp-2023-002238',
'relation': {},
'ISSN': ['2052-4439'],
'subject': ['Pulmonary and Respiratory Medicine'],
'container-title-short': 'BMJ Open Resp Res',
'published': {'date-parts': [[2024, 4]]}}
